Published • loading... • Updated
Johnson & Johnson's Robotic Surgery Device Gets US FDA Marketing Authorization
The device can be used in upper-abdominal procedures and occupies 30% to 50% less space than traditional surgical robots, J&J said.
- On Wednesday, the U.S. Food and Drug Administration granted marketing authorization to Johnson & Johnson for its Ottava robotic surgery system, clearing the company to enter the soft-tissue robotic surgery market.
- Seeking to challenge Intuitive Surgical's market dominance, J&J developed Ottava to compete directly with the da Vinci platform, which has long dominated the robotic-assisted surgery market.
- Designed for space efficiency, Ottava integrates robotic arms directly into the operating table, reducing the system's physical footprint by 30% to 50% compared to conventional boom- or cart-mounted systems.
- Following the earlier-than-expected approval, J&J shares rose 2% as analysts at Stifel noted the launch will take a "deliberate and phased approach" with significant training requirements.
- Positioning Ottava as "one of the most significant MedTech innovations" of the decade, J&J plans a comprehensive training framework for clinicians while expanding the system into additional surgical indications.
Insights by Ground AI
18 Articles
18 Articles
Johnson & Johnson’s robotic surgery device gets U.S. marketing authorization
Johnson & Johnson said on Wednesday the U.S. Food and Drug Administration had granted marketing authorization for its robotic surgery device, clearing the way for the healthcare conglomerate to enter the soft-tissue robotic surgery market.
·Toronto, Canada
Read Full Article
·London, United Kingdom
Read Full Article
Coverage Details
Total News Sources18
Leaning Left2Leaning Right3Center8Last UpdatedBias Distribution62% Center
Bias Distribution
- 62% of the sources are Center
62% Center
15%
C 62%
R 23%
Factuality
To view factuality data please Upgrade to Premium
